Home / Health / Zydus Lifesciences Approved to Sell Antidepressant in China
Zydus Lifesciences Approved to Sell Antidepressant in China
11 Nov
Summary
- Zydus Lifesciences receives approval from Chinese regulator for Venlafaxine ER capsules
- Medication treats major depressive disorder, anxiety, and panic disorders
- First approval for Zydus in China
In a significant development, Zydus Lifesciences, the Gujarat-based pharmaceutical firm, has received approval from China's National Medical Products Administration (NMPA) to market its Venlafaxine extended-release (ER) capsules in the country.
The approved strengths of the medication are 75 mg and 150 mg, and it is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Venlafaxine ER helps restore the balance of serotonin and norepinephrine in the brain, thereby improving mood and reducing anxiety.
This approval marks the first time Zydus Lifesciences has received the green light from the Chinese regulator to sell its products in the world's second-largest pharmaceutical market. The company's shares were trading 0.84% lower at Rs 939.05 on the Bombay Stock Exchange as of November 11, 2025.
The successful regulatory clearance in China is a significant milestone for Zydus Lifesciences, as it looks to expand its global footprint and cater to the growing demand for effective treatments for mental health conditions in the Asian economic powerhouse.
